📣 VC round data is live. Check it out!
- Public Comps
- Atrys Health
Atrys Health Valuation Multiples
Discover Atrys Health's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Goodwill Pharma, MediClin, Australian Clinical Labs, Humana and more.
Atrys Health Overview
About Atrys Health
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Founded
2007
HQ

Employees
62
Website
Sectors
Financials (LTM)
EV
$526M
Valuation Multiples
Start free trialAtrys Health Financials
Atrys Health reported last 12-month revenue of $193M and EBITDA of $30M.
In the same LTM period, Atrys Health generated $107M in gross profit, $30M in EBITDA, and had net loss of ($8M).
Revenue (LTM)
Atrys Health P&L
In the most recent fiscal year, Atrys Health reported revenue of $188M and EBITDA of $27M.
Atrys Health is unprofitable as of last fiscal year, with gross margin of 38%, EBITDA margin of 14%, and net margin of (6%).
Financial data powered by Morningstar, Inc.
Atrys Health Stock Performance
Atrys Health has current market cap of $241M, and enterprise value of $526M.
Market Cap Evolution
Atrys Health's stock price is $3.17.
Atrys Health share price decreased by 3.3% in the last 30 days, and increased by 7.5% in the last year.
Atrys Health has an EPS (earnings per share) of $-0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $526M | $241M | -3.3% | -3.3% | -6.3% | 7.5% | $-0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAtrys Health Valuation Multiples
Atrys Health trades at 2.7x EV/Revenue multiple, and 17.6x EV/EBITDA.
EV / Revenue (LTM)
Atrys Health Financial Valuation Multiples
As of June 2, 2026, Atrys Health has market cap of $241M and EV of $526M.
Atrys Health has a P/E ratio of (28.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Atrys Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Atrys Health Margins & Growth Rates
Atrys Health grew revenue by 7% and EBITDA by 23% in the last fiscal year.
In the most recent fiscal year, Atrys Health reported gross margin of 38%, EBITDA margin of 14%, and net margin of (6%).
Atrys Health Margins
Atrys Health Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Atrys Health Operational KPIs
Atrys Health's revenue per employee in the last FY averaged $3.0M, while opex per employee averaged $1.3M for the same period.
Atrys Health's Rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atrys Health's Rule of X is 72% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Atrys Health Competitors
Atrys Health competitors include Goodwill Pharma, MediClin, Australian Clinical Labs, Humana, Pihlajalinna, Monash IVF Group, Clinica Las Condes, Lucid Diagnostics, Korro Bio and Oncoclínicas.
Most Atrys Health public comparables operate across Diagnostics & Genomics, Medical Imaging & Diagnostics, Hospitals & Clinics, BioTech, DeepTech, HealthTech and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.0x | - | 11.2x | - | |||
| 0.5x | 0.5x | 3.7x | 3.5x | |||
| 0.9x | 0.9x | 3.6x | 3.5x | |||
| 0.7x | 0.7x | 6.1x | 6.1x | |||
| 0.6x | 0.7x | 3.7x | 4.0x | |||
| 1.7x | 1.8x | 7.4x | 8.0x | |||
| 2.7x | - | (5.9x) | - | |||
| 43.7x | 35.3x | (3.6x) | (3.9x) | |||
This data is available for Pro users. Sign up to see all Atrys Health competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Atrys Health
Atrys Health has acquired 4 companies to date.
Last acquisition by Atrys Health was on June 13th 2022. Atrys Health acquired Bienzobas for $82M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Atrys Health
| Description | Bienzobas is an Almeria-based Spanish provider of oncology treatment validation services for insurers and hospital groups. The company reviews proposed therapies to identify inefficiencies, reducing unwarranted expenses through expert analysis, serving public health systems and private networks across Andalusia and national providers since 2010. | Lenitudes is a Portuguese healthcare group operating medical centers in Lisbon focused on oncology, radio-diagnostics, and radiotherapy. The facilities provide imaging, chemotherapy, and clinical support services in integrated clinics. Lenitudes serves patients from Portugal and neighboring countries with specialized teams in breast and lung cancer care. Established in 2018, it expanded to two locations equipped with linear accelerators and PET-CT scanners. | AxisMed is a São Paulo-based provider of chronic disease management programs in Brazil. Introduced in 2002, it applies international prevention and care protocols to monitor clinical conditions, enhance doctor-patient interactions, and reduce unnecessary hospitalizations. AxisMed has supported over 280,000 participants through telehealth services, family involvement tools, and data-driven interventions for conditions like diabetes and hypertension. | Real Life Data is a Madrid-based specialist in healthcare big data and real-world evidence from Spain. Processes electronic health records, claims databases, and registries to analyze disease epidemiology, treatment patterns, and outcomes. Delivers studies for pharmaceutical firms on oncology, cardiology, and rare diseases using anonymized datasets from national health systems. Pioneers RWE platforms since 2014 supporting EMA and AEMPS regulatory submissions. |
| HQ Country | ||||
| HQ City | Almería | Aveiro | São Paulo | Madrid |
| Deal Date | 13 Jun 2022 | 10 Nov 2020 | 19 Aug 2020 | 10 Jun 2019 |
| Valuation | $82M | $21M | $2M | $16M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Atrys Health acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Atrys Health
| When was Atrys Health founded? | Atrys Health was founded in 2007. |
| Where is Atrys Health headquartered? | Atrys Health is headquartered in Spain. |
| How many employees does Atrys Health have? | As of today, Atrys Health has over 62 employees. |
| Is Atrys Health publicly listed? | Yes, Atrys Health is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Atrys Health? | Atrys Health trades under ATRY ticker. |
| When did Atrys Health go public? | Atrys Health went public in 2016. |
| Who are competitors of Atrys Health? | Atrys Health main competitors include Goodwill Pharma, MediClin, Australian Clinical Labs, Humana, Pihlajalinna, Monash IVF Group, Clinica Las Condes, Lucid Diagnostics, Korro Bio, Oncoclínicas. |
| What is the current market cap of Atrys Health? | Atrys Health's current market cap is $241M. |
| What is the current revenue of Atrys Health? | Atrys Health's last 12 months revenue is $193M. |
| What is the current revenue growth of Atrys Health? | Atrys Health revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Atrys Health? | Current revenue multiple of Atrys Health is 2.7x. |
| What is the current EBITDA of Atrys Health? | Atrys Health's last 12 months EBITDA is $30M. |
| What is Atrys Health's EBITDA margin? | Atrys Health's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Atrys Health? | Current EBITDA multiple of Atrys Health is 17.6x. |
| What is the current FCF of Atrys Health? | Atrys Health's last 12 months FCF is $5M. |
| What is Atrys Health's FCF margin? | Atrys Health's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Atrys Health? | Current FCF multiple of Atrys Health is 111.6x. |
| How many companies Atrys Health has acquired to date? | As of June 2026, Atrys Health has acquired 4 companies. |
| What was the largest acquisition by Atrys Health? | $82M acquisition of Bienzobas on 13th June 2022 was the largest M&A Atrys Health has done to date. |
| What companies Atrys Health acquired? | Atrys Health acquired Bienzobas, Lenitudes, Real Life Data, and AxisMed. |
| In how many companies Atrys Health has invested to date? | Atrys Health hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Atrys Health
Lists including Atrys Health
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


